Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Metastatic and recurrent anal squamous cell carcinoma, drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Median survival remains under two years even with a PD-1 antibody added to chemotherapy.
No second-line standard exists after chemo-immunotherapy.
Whether local treatment of oligometastases improves survival has never been randomised.
HPV-directed cell therapies and vaccines are promising but early.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
Median progression-free survival 9.
A milestone in how this cancer is treated.
Response rate 57 percent with cisplatin-fluorouracil against 59 percent with carboplatin-paclitaxel; serious adverse events 62 against 36 percent; median overall survival 12.
A milestone in how this cancer is treated.
Nivolumab alone: objective response 24 percent in 37 previously treated patients.